A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease.

Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMINI-II
  • Sponsors Millennium
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2017 According to a Takeda Pharmaceutical media release, results of post-hoc analysis of GEMINI-1 and GEMINI-II presented at he 2017 Digestive Disease Week (DDW) annual scientific meeting.
    • 07 Feb 2017 Pooled results assessing pregnancy outcomes from six clinical studies and post marketing safety data published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top